PRMT5 as a druggable target for glioblastoma therapy.
Banasavadi-Siddegowda YK, Welker AM, An M, Yang X, Zhou W, Shi G, Imitola J, Li C, Hsu S, Wang J, Phelps M, Zhang J, Beattie CE, Baiocchi R, Kaur B.
Banasavadi-Siddegowda YK, et al. Among authors: wang j.
Neuro Oncol. 2018 May 18;20(6):753-763. doi: 10.1093/neuonc/nox206.
Neuro Oncol. 2018.
PMID: 29106602
Free PMC article.